This clinical trial is looking at two types of brachytherapy for treating early-stage endometrial cancer. Endometrial cancer is a common type of cancer that starts in the lining of the uterus. The trial will compare a shorter course of treatment with the usual longer course to see which works better. The goal is to find out how these treatments affect patients' quality of life and financial burden after treatment.
The trial's ID number is NCT03422198. This is a Phase 3 trial, which means it is looking at how well the treatments work and how safe they are. The trial is not for a new drug but involves a regulated treatment device. It aims to include about 188 participants.
Who can join
This study is open to adults of all ages, including children and older adults, who have confirmed early-stage endometrial cancer. Participants must have had surgery and be free from remaining cancer. The trial is not for those who have had pelvic radiation before or have other active cancers. The team will confirm if you can join.
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage IA Uterine Corpus Cancer, Stage IB Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Uterine Corpus Carcinosarcoma, Uterine Corpus Sarcoma
Age group
All ages
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants in the trial will be placed into two groups by chance. One group will receive a shorter course of brachytherapy with two treatments. The other group will receive the standard treatment, which consists of three to five treatments. Everyone will be monitored for their quality of life and any financial concerns after their treatment.
Where
This trial is running at 5 locations in the United States. 3 of them are currently recruiting.